These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26583637)
1. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. Kreamer K; Riordan D Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Chuang JC; Neal JW; Niu XM; Wakelee HA Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476 [TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058 [TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. Klempner SJ; Ou SH Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806 [TBL] [Abstract][Full Text] [Related]
7. Update on systemic therapy of advanced non-small-cell lung cancer. Cufer T; Knez L Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682 [TBL] [Abstract][Full Text] [Related]
8. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. Minguet J; Smith KH; Bramlage P Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074 [TBL] [Abstract][Full Text] [Related]
10. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Genova C; Rijavec E; Biello F; Rossi G; Barletta G; Dal Bello MG; Vanni I; Coco S; Alama A; Grossi F Expert Opin Pharmacother; 2017 Jan; 18(1):19-33. PubMed ID: 27841028 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
12. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Dikopf A; Wood K; Salgia R Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177 [TBL] [Abstract][Full Text] [Related]
14. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
15. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the anaplastic lymphoma kinase. Mologni L Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599 [TBL] [Abstract][Full Text] [Related]
17. Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. Rolfo C; Passiglia F; Ostrowski M; Farracho L; Ondøichová T; Dolcan A; Castiglia M; Remmen R; Papadimitriou K; Pauwels P J Am Board Fam Med; 2015; 28(1):124-33. PubMed ID: 25567833 [TBL] [Abstract][Full Text] [Related]